Molecular pathology in epidemiologic studies: A primer on key considerations

Mark E. Sherman, Will Howatt, Fiona M. Blows, Paul Pharoah, Stephen M. Hewitt, Montserrat Garcia-Closas

Research output: Contribution to journalShort survey

29 Citations (Scopus)

Abstract

The development of molecular pathologic components in epidemiologic studies offers opportunities to relate etiologic factors to specific tumor types, which in turn may allow the development of better overall risk prediction and provide clues about mechanisms that mediate risk factors. In addition, this research may help identify or validate tissue biomarkers related to prognosis and prediction of treatment responses. In this mini review, we highlight specific considerations related to the incorporation of pathology in epidemiologic studies, using breast cancer research as a model. Issues related to ensuring the representativeness of cases for which research tissue is available and understanding limitations resulting from variable procedures for tissue collection, fixation, and processing are discussed. The growing importance of molecular pathology in clinical medicine has led to increased emphasis on optimized tissue preparation, which should enhance this type of research. In addition, the availability of new technologies including tissue microarrays, image scanning, and automated analysis to achieve high-throughput standardized assessment of immunohistochemical markers, and potentially other assays, is enabling consistent scoring of a growing list of markers in large studies. Concurrently, methodologie research to extend the range of assays that can be done on fixed tissues is expanding possibilities for molecular pathologic studies in epidemiologic research.

Original languageEnglish (US)
Pages (from-to)966-972
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume19
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Molecular Pathology
Epidemiologic Studies
Research
Tissue Fixation
Clinical Medicine
Biomarkers
Pathology
Breast Neoplasms
Technology
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Molecular pathology in epidemiologic studies : A primer on key considerations. / Sherman, Mark E.; Howatt, Will; Blows, Fiona M.; Pharoah, Paul; Hewitt, Stephen M.; Garcia-Closas, Montserrat.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 19, No. 4, 04.2010, p. 966-972.

Research output: Contribution to journalShort survey

Sherman, Mark E. ; Howatt, Will ; Blows, Fiona M. ; Pharoah, Paul ; Hewitt, Stephen M. ; Garcia-Closas, Montserrat. / Molecular pathology in epidemiologic studies : A primer on key considerations. In: Cancer Epidemiology Biomarkers and Prevention. 2010 ; Vol. 19, No. 4. pp. 966-972.
@article{1032032f454b484e968d650e00898764,
title = "Molecular pathology in epidemiologic studies: A primer on key considerations",
abstract = "The development of molecular pathologic components in epidemiologic studies offers opportunities to relate etiologic factors to specific tumor types, which in turn may allow the development of better overall risk prediction and provide clues about mechanisms that mediate risk factors. In addition, this research may help identify or validate tissue biomarkers related to prognosis and prediction of treatment responses. In this mini review, we highlight specific considerations related to the incorporation of pathology in epidemiologic studies, using breast cancer research as a model. Issues related to ensuring the representativeness of cases for which research tissue is available and understanding limitations resulting from variable procedures for tissue collection, fixation, and processing are discussed. The growing importance of molecular pathology in clinical medicine has led to increased emphasis on optimized tissue preparation, which should enhance this type of research. In addition, the availability of new technologies including tissue microarrays, image scanning, and automated analysis to achieve high-throughput standardized assessment of immunohistochemical markers, and potentially other assays, is enabling consistent scoring of a growing list of markers in large studies. Concurrently, methodologie research to extend the range of assays that can be done on fixed tissues is expanding possibilities for molecular pathologic studies in epidemiologic research.",
author = "Sherman, {Mark E.} and Will Howatt and Blows, {Fiona M.} and Paul Pharoah and Hewitt, {Stephen M.} and Montserrat Garcia-Closas",
year = "2010",
month = "4",
doi = "10.1158/1055-9965.EPI-10-0056",
language = "English (US)",
volume = "19",
pages = "966--972",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Molecular pathology in epidemiologic studies

T2 - A primer on key considerations

AU - Sherman, Mark E.

AU - Howatt, Will

AU - Blows, Fiona M.

AU - Pharoah, Paul

AU - Hewitt, Stephen M.

AU - Garcia-Closas, Montserrat

PY - 2010/4

Y1 - 2010/4

N2 - The development of molecular pathologic components in epidemiologic studies offers opportunities to relate etiologic factors to specific tumor types, which in turn may allow the development of better overall risk prediction and provide clues about mechanisms that mediate risk factors. In addition, this research may help identify or validate tissue biomarkers related to prognosis and prediction of treatment responses. In this mini review, we highlight specific considerations related to the incorporation of pathology in epidemiologic studies, using breast cancer research as a model. Issues related to ensuring the representativeness of cases for which research tissue is available and understanding limitations resulting from variable procedures for tissue collection, fixation, and processing are discussed. The growing importance of molecular pathology in clinical medicine has led to increased emphasis on optimized tissue preparation, which should enhance this type of research. In addition, the availability of new technologies including tissue microarrays, image scanning, and automated analysis to achieve high-throughput standardized assessment of immunohistochemical markers, and potentially other assays, is enabling consistent scoring of a growing list of markers in large studies. Concurrently, methodologie research to extend the range of assays that can be done on fixed tissues is expanding possibilities for molecular pathologic studies in epidemiologic research.

AB - The development of molecular pathologic components in epidemiologic studies offers opportunities to relate etiologic factors to specific tumor types, which in turn may allow the development of better overall risk prediction and provide clues about mechanisms that mediate risk factors. In addition, this research may help identify or validate tissue biomarkers related to prognosis and prediction of treatment responses. In this mini review, we highlight specific considerations related to the incorporation of pathology in epidemiologic studies, using breast cancer research as a model. Issues related to ensuring the representativeness of cases for which research tissue is available and understanding limitations resulting from variable procedures for tissue collection, fixation, and processing are discussed. The growing importance of molecular pathology in clinical medicine has led to increased emphasis on optimized tissue preparation, which should enhance this type of research. In addition, the availability of new technologies including tissue microarrays, image scanning, and automated analysis to achieve high-throughput standardized assessment of immunohistochemical markers, and potentially other assays, is enabling consistent scoring of a growing list of markers in large studies. Concurrently, methodologie research to extend the range of assays that can be done on fixed tissues is expanding possibilities for molecular pathologic studies in epidemiologic research.

UR - http://www.scopus.com/inward/record.url?scp=77950795113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950795113&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-10-0056

DO - 10.1158/1055-9965.EPI-10-0056

M3 - Short survey

C2 - 20332257

AN - SCOPUS:77950795113

VL - 19

SP - 966

EP - 972

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -